The cause of bleeding should be determined before using dehydroprogesterone to treat abnormal bleeding. During the treatment of dehydroprogesterone, the liver function occasionally changes, sometimes accompanied by clinical symptoms. Therefore, patients with acute liver disease or a history of liver disease and whose liver function has not returned to normal should be careful with desdrogesterone. Once severe liver damage occurs, the drug should be stopped. A few patients may have breakthrough bleeding. [u] Conditions to be monitored [/u] Patients should be closely monitored if the following conditions exist, have occurred and/or worsened during pregnancy and previous hormone therapy. It should be considered that these conditions may recur or worsen during the treatment with drogesterone, especially: 1 .porphyria 2. Depression [u] Other symptoms [/u] Suffering from galactose intolerance. Patients with rare genetic diseases such as Lapp lactase deficiency or glucose-galactose absorption disorder should not take this medicine. Warnings and precautions for local use of drogesterone to prevent endometrial hyperplasia in women who use estrogen; Note: You can also refer to the warning in the product information of estrogen drugs. Hormone replacement therapy (HRT) should only be used when symptoms have an adverse effect on the quality of life. Carefully evaluate the benefits and risks of HRT on a regular basis (at least once a year), and continue HRT treatment only if the benefits outweigh the disadvantages. A complete medical history (including family history) should be collected for medical examination/follow-up before starting hormone replacement therapy (HRT) or when it is re-applied after interruption. Physical examination (including gynecological and breast examination) must be carried out under the guidance of medical history, contraindications and warnings. During the treatment, it is suggested to adjust the frequency and content of regular examination according to individual circumstances. Female patients should be informed that when breast changes occur, they should report to the doctor. Regular breast examination (including mammography) should be carried out according to the current guidelines for healthy women and the medical needs of female patients. Long-term use of estrogen instead of progesterone for endometrial hyperplasia will increase the incidence of endometrial hyperplasia and endometrial cancer in women with uterus. In each menstrual cycle, the combined use of estrogen and progesterone (such as desdrogesterone) for at least 12 days may prevent this risk to a great extent. In the first few months of treatment, occasional breakthrough bleeding and drip bleeding will occur. If breakthrough bleeding and dripping bleeding occur after a period of treatment, or continue to exist after the treatment is stopped, the cause of bleeding should be investigated, and endometrial biopsy can be performed to rule out the possibility of endometrial malignant transformation. When abnormal vaginal bleeding occurs, further examination should be done. A randomized placebo-controlled study on breast cancer, namely the Women's Health Promotion Study (WHI) and some epidemiological studies (including the Million Women Study (MWS)), shows that the risk of breast cancer is relatively increased for female patients who have been taking estrogen, estrogen-progesterone combination or tibolone as hormone replacement therapy for many years. For all HRT, this risk will appear in the first few years of use, and will increase with the extension of medication time, and the risk will drop to the pre-treatment level within a few years (up to 5 years) after drug withdrawal. MWS research shows that women who are treated with conjugated estrogen (CEE) or estradiol (E2) have a higher relative risk of breast cancer after adding progesterone. This risk has nothing to do with dosage regimen (sequential or continuous administration of progesterone) and progesterone type. Hormone replacement therapy for venous thromboembolism is associated with higher relative risk (VTE). A randomized controlled study and some epidemiological studies found that the VTE risk of HRT users increased by 2-3 times compared with that of women who did not use VTE. In the first year of HRT treatment, the incidence of VTE is higher than that in the subsequent treatment period. The general risk factors of VTE are: positive personal history; Family history is positive; Severe obesity (body mass index > 30kg/m [sup] 2 [/sup]); Systemic lupus erythematosus (SLE). The possible role of varicose veins in VTE has not been recognized. The incidence of VTE increased in patients with a history of VTE recurrence or thrombosis tendency. Hormone replacement therapy will further increase this risk. Those who have a personal or exact family history of VTE or recurrent spontaneous abortion must be investigated first to rule out the tendency of thrombosis. HRT is prohibited for these patients unless the comprehensive evaluation of thrombosis factors has been completed or anticoagulation treatment has been carried out. For women who have received anticoagulant therapy, it is necessary to carefully evaluate the advantages and disadvantages of HRT therapy. Long-term inactivity. During severe trauma or major surgery, the possibility of venous thromboembolism will temporarily increase. All postoperative patients must pay close attention to postoperative preventive measures to prevent postoperative venous thromboembolism. If the patient is expected to be inactive for a long time after elective surgery (especially abdominal or lower limb plastic surgery), it is necessary to consider interrupting HRT for 4-6 weeks before surgery, and then restart HRT after the patient fully recovers his activities. If venous thromboembolism occurs after starting treatment, the drug must be stopped. Patients must be informed that if there are possible symptoms of thrombosis, they should contact the doctor immediately (for example, pain in one leg, sudden chest pain and shortness of breath). Randomized controlled studies of coronary heart disease have not provided evidence that the continuous combination of conjugated estrogen and medroxyprogesterone acetate is beneficial to the risk of coronary heart disease. Two large clinical studies (WHI and HERS[ Heart and Estrogen/Progesterone Replacement Therapy]) show that the risk of cardiovascular disease may increase in the first year of treatment, with no beneficial effect on the whole. Cerebrovascular accident (CVA) A large randomized clinical trial ({WHI study) in healthy women reported that the continuous combination of estrogen and medroxyprogesterone acetate increased the risk of ischemic CVA (the secondary end point of this study). Desdrogesterone has no or little effect on the ability to drive and operate machines.